Automated Insulin Delivery in Adults With Advanced Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-01

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney failure inject themselves with insulin and do finger-prick blood glucose tests. Managing diabetes in people with advanced kidney disease is hard, with fluctuating glucose levels and an increased risk of unsafe low glucose levels.

There are currently continuous glucose monitors (CGM), which allow people to monitor glucose without painful fingerprick tests. CGM can be combined with insulin pumps to create automated insulin delivery systems (AID) that deliver insulin automatically to control glucose. AID systems are currently used in people with type 1 diabetes, but they are not used in people with type 2 diabetes. There is little information on how these systems might help people with diabetes and advanced kidney failure and on dialysis.

This study will investigate whether automated insulin delivery can improve glucose levels and quality of life in people with diabetes treated with more than one insulin injection with advanced kidney failure and/or undergoing regular dialysis treatment. This study will be a feasibility study conducted in a single centre (Imperial College, London) and be of a cross-over design. The study will aim to complete 12 people. Participants will wear a glucose sensor at the start. In random order, half will start AID followed by the usual treatment, while the other half will start the usual treatment followed by AID treatment. The duration of each treatment stage is eight weeks. The study will last about 22 weeks for each participant. Investigators will compare the glucose levels in the AID group with the usual care group to see if there is a difference. Questionnaires and interviews will help us understand participants' experiences. Investigators will carefully monitor the safety of participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump

NCT06207838

Diabetes Type 1

ENROLLING_BY_INVITATION NA

Closed-loop in Adults With T2D Requiring Dialysis

NCT04025775

Type 2 Diabetes End Stage Renal Disease

COMPLETED NA

Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease

NCT06330194

Dialysis Chronic Kidney Disease Diabetes Mellitus, Type 2 +3 more

COMPLETED NA

Closed-loop in Adults With T2D Not Requiring Dialysis

NCT04701424

Type 2 Diabetes

COMPLETED NA

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943

Type 1 Diabetes Gastroparesis Due to Diabetes Mellitus Type I

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a single-centre, prospective, open-label, two-stage, randomized crossover study comparing automated subcutaneous insulin delivery (AID), also known as Hybrid Closed Loop (HCL) therapy using the 780G system with usual insulin therapy plus continuous glucose monitoring (CGM) in people with type 1 and type 2 diabetes complicated by advanced renal disease and managed with insulin. The study will be conducted at Imperial College Healthcare NHS Trust.

Duration of each treatment arm is 8 weeks

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Automated insulin delivery using Medtronic 780G System

Group Type EXPERIMENTAL

Medtronic 780G System

Intervention Type DEVICE

Automated insulin delivery using Medtronic 780G system

Usual care plus continuous glucose monitoring

Group Type OTHER

Continuous Glucose Monitoring

Intervention Type DEVICE

Usual care with continuous glucose monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medtronic 780G System

Automated insulin delivery using Medtronic 780G system

Intervention Type DEVICE

Continuous Glucose Monitoring

Usual care with continuous glucose monitoring

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Age 18-70 years inclusive
* 2\. Type 1 diabetes of at least 1-year duration or insulin-requiring type 2 diabetes managed with multiple daily injections (MDI \[ie separate rapid-acting and basal insulin injections\]) or insulin pump therapy (CSII)
* 3\. The HbA1c \<10.5% (\<91 mmol/mol)
* 4\. The total daily dose of insulin \<200Units
* 5\. The participant is willing and able to implement the study requirements.
* 6\. Participant has advanced renal disease (Group A: Stage 3b or greater renal failure (eGFR \<45millilitres/minute/1.73m2); Group B: ESKD requiring peritoneal dialysis; Group C: ESKD requiring haemodialysis
* 7\. Participants (and carer where applicable) should be able to speak and understand English sufficiently for safe study conduct
* 8\. The participant has internet or smartphone access, enabling upload of the 780G system data to cloud-based software

Exclusion Criteria

* 1\. The participant is already using an AID system
* 2\. The participant is treated with sulphonylureas (SGLT2 inhibitors, metformin, and GLP1 analogues may be used within regulatory guidelines) in pre-dialysis participants (Group A). In Groups B \& C, noninsulin glucose-lowering therapies are not permitted, with the exception of GLP1 agonists used in preparation for transplantation
* 3\. The participant has a recent history of diabetic ketoacidosis (\<6 months)
* 4\. The use of systemic steroid therapy within the past four weeks (stable doses of steroids for \>8 weeks permitted)
* 5\. The participant has significant cognitive impairment or major psychiatric history affecting safe study conduct
* 6\. Known significant allergy to tape/ adhesives
* 7\. Women who are pregnant or planning pregnancy
* 8\. The participant has an active major life-threatening illness limiting the participants life expectancy to \<6 months
* 9\. The participant is on hydroxyurea treatment or taking regular / daily paracetamol treatment (sensor interference)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No